Safety and Efficacy of Glucomannan for Weight Loss in Overweight and Moderately Obese Adults

Author:

Keithley Joyce K.1,Swanson Barbara1,Mikolaitis Susan L.2,DeMeo Mark3,Zeller Janice M.4,Fogg Lou5,Adamji Jehan6

Affiliation:

1. Rush University College of Nursing, 600 S. Paulina Street, Suite 1080, Chicago, IL 60612, USA

2. Rush University Medical Center, 1725 W. Harrison Street, Chicago, IL 60612, USA

3. Section of Gastroenterology and Nutrition, Rush University Medical Center, 1725 W. Harrison Street, Chicago, IL 60612, USA

4. North Park University School of Nursing, 3225 W. Foster Avenue, Chicago, IL 60625, USA

5. Community, Systems, and Mental Health Nursing, Rush University College of Nursing, 600 S. Paulina Street, Suite 1080, Chicago, IL 60612, USA

6. Faculty Practice, Rush University College of Nursing, 600 S. Paulina Street, Suite 1080, Chicago, IL 60612, USA

Abstract

Background. Few safe and effective dietary supplements are available to promote weight loss. We evaluated the safety and efficacy of glucomannan, a water-soluble fiber supplement, for achieving weight loss in overweight and moderately obese individuals consuming self-selected diets.Methods. Participants were randomly assigned to take 1.33 grams of glucomannan or identically looking placebo capsules with 236.6 mL (8 ounces) of water one hour before breakfast, lunch, and dinner for 8 weeks. The primary efficacy outcome was change in body weight after 8 weeks. Other efficacy outcomes were changes in body composition, hunger/fullness, and lipid and glucose concentrations. Safety outcomes included gastrointestinal symptoms/tolerance and serum liver enzymes and creatinine levels.Results. A total of 53 participants (18–65 years of age; BMI 25–35 kg/m2) were enrolled and randomized. The two groups did not differ with respect to baseline characteristics and compliance with the study supplement. At 8 weeks, there was no significant difference between the glucomannan and placebo groups in amount of weight loss (.40±.06and.43±.07, resp.) or other efficacy outcomes or in any of the safety outcomes.Conclusions. Glucomannan supplements administered over 8 weeks were well tolerated but did not promote weight loss or significantly alter body composition, hunger/fullness, or lipid and glucose parameters. This trial is registered withNCT00613600.

Funder

Roberts Trust Fund, Chicago, IL.

Publisher

Hindawi Limited

Subject

Endocrinology, Diabetes and Metabolism

Cited by 53 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3